Necrostatin-1

For research use only. Not for use in humans.

目录号:S8037

Necrostatin-1 Chemical Structure

CAS No. 4311-88-0

Necrostatin-1是一种特异性RIP1 (RIPK1)抑制剂,抑制TNF-α诱导的细胞坏死,在293T细胞中EC50为490 nM。Necrostatin-1也可抑制 IDO、细胞自噬和凋亡。

规格 价格 库存 购买数量  
RMB 814.14 现货
RMB 2224.79 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Necrostatin-1发表文献61篇:

产品安全说明书

RIP kinase抑制剂选择性比较

生物活性

产品描述 Necrostatin-1是一种特异性RIP1 (RIPK1)抑制剂,抑制TNF-α诱导的细胞坏死,在293T细胞中EC50为490 nM。Necrostatin-1也可抑制 IDO、细胞自噬和凋亡。
特性 Necrostatin-1是抑制细胞坏死的有力工具。
靶点
RIP1 [1]
(293T cells)
490 nM(EC50)
体外研究

Necrostatin-1 (1-100 μM) 抑制过表达和内源性的RIP1发生自磷酸化。RIP1是初级细胞靶点,负责Necrostatin-1的抗细胞坏死活性。[1] Necrostatin-1有效抑制多种类型细胞触发的坏死性细胞死亡。Necrostatin-1作为细胞坏死的小分子抑制剂, 作用于jurkat细胞,抑制RIP激酶的诱导细胞坏死,抑制TNF-α诱导的细胞坏死,EC50为490 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MkDSR4VtdCCYaXHibYxqfHliQYPzZZk> MUm1NOKh|ryP M{K2TFI1yqCq MlLTbY5pcWKrdIOgUW1UNWmwZIXj[YQh[2WubDDk[YF1cA>? M4\OblI3PDd{N{Kz
MEFs  NEjJNXRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV:wUnJ5OTEkgJpOwG0> MUi0PEBp M2\YO2ROW09? MnW2bY5pcWKrdIOgfnZCTC2ycn;tc5Rm\CCmZXH0bEBw\iCFTl;UN{1l\XCuZYTl[EBOTU[| NX3seVc2OjZ2M{e3PFk>
BMDM  M2\jRWZ2dmO2aX;uJGF{e2G7 NHfGSG0yOMLizszN MmXjN|DDqG2rbh?= M1naTZBzd3SnY4TzJINmdGy|IH\yc40hXEGNST3pcoR2[2WmIFzETEBz\WynYYPl M2P0b|I3OzhzNkCx
NCI-H28 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYPYN2RPOTEEoN88US=> M{PEbFI1yqCq M1H6eZBz\X[nboTzJGRCWEVvaX7keYNm\CC{ZXT1Z5Rqd25ib3[gUmNKNUh{ODDj[YxtKH[rYXLpcIl1gcLi MkTQNlYxODRzM{i=
MiaPaCa-2 MlKxSpVv[3Srb36gRZN{[Xl? MWmyNEDPxE1? Mo\jNlQhcA>? Mmq0[IVkemWjc3XzJJRp\SCnYYLsfUBv\WO{b4TpZ{Bk\Wyucx?= M4PuR|I3ODByNkC3
BxPC-3 NFzFRopHfW6ldHnvckBCe3OjeR?= NEm4W2kzOCEQvF2= Ml61NlQhcA>? M{DyWoRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= NGf4SlgzPjByME[wOy=>
SGC-7901 M4ntUGNmdGxiVnnhZoltcXS7IFHzd4F6 NVXvXGV[OzEEoN88US=> NYrhSFhmOcLiaB?= MnHZd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq Ml;qNlU4PjdyN{[=
KMS-12-PE  MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1T1dVYxKM7:TR?= MoL1OUBp M3fKOYlvcGmkaYTzJHNJUy2rbnT1Z4VlKGOnbHyg[IVifGh? MYiyOVU{ODB7OB?=
L929-A  NUXyN3BES2WubDDWbYFjcWyrdImgRZN{[Xl? NU\xNXRiPTEEoN88UeKh M1LRPFI1KGh? NYC0UFI{[myxY3vzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?= NYTSVFZVOjV|OUi1OFA>
L929-N  NGW0Xo9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3nXUVUxyqEQvF5CpC=> NHu5[FkzPCCq MlXuZoxw[2u|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>? MW[yOVM6QDV2MB?=
L929-A  MX;GeY5kfGmxbjDBd5NigQ>? M4Pwb|UxyqEQvF5CpC=> NVX6OJdwOTJiaB?= Mmq2Zoxw[2u|IITo[UBkdGWjdnHn[UBw\iCFYYPwZZNmNTNiYX7kJHBCWlB? MUOyOVM6QDV2MB?=
L929-N  MV3GeY5kfGmxbjDBd5NigQ>? MVK1NOKh|ryPwrC= M1H2UlEzKGh? NWnVWllz[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC= NIG4O2kzPTN7OEW0NC=>
L929 MU\GeY5kfGmxbjDBd5NigQ>? MXS1NOKh|ryPwrC= NWXTUVhMOTJiaB?= NGXh[FRqdmirYnn0d{BVVkcQsT3pcoR2[2WmIFLp[EBkdGWjdnHn[S=> M3Xze|I2Ozl6NUSw
L929-A MnzuSpVv[3Srb36gRZN{[Xl? NXL6[IpbPTEEoN88UeKh MkLINVIhcA>? M1\pT4lvcGmkaYTzJJRp\SCWTldOtU1qdmS3Y3XkJIxwe3Nib3[gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyZYLt[YFjcWyrdIm= NXGzSZB[OjV|OUi1OFA>
L929 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmXHN|DDqM7:TR?= NVPLUJE1OcLiaB?= NIXPWndqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 MV[yOVA6PTd2Mh?=
L929 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NU\NZ3lROzEEoN88US=> MojXNeKhcA>? NULOcXhscW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ4xm[X[jZ3Wgc4YhXG:ybzDJ NFrKXY0zPTB7NUe0Ni=>
Huh7 NWLKe3ZlS2WubDDWbYFjcWyrdImgRZN{[Xl? MnPOOVAhyrWP MUGyOE81QCCq Ml7jSG1UVw>? M{f2OpBz\X[nboTzJINmdGxiZHXheIghd2ZiclHkTGNXKGOxLXnu[oVkfGWmIFj1bFch[2WubIO= M{nMdlI1QTd|MkSw
OHC M2jlRmZ2dmO2aX;uJGF{e2G7 MYizNFDjiIoQvF2= NGDQfZBFVVOR NIDjUllqdmO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDjc45l\W6|ZXSgcpVkdGWr MlvVNlQ5PzR5M{S=
OHC MXLGeY5kfGmxbjDBd5NigQ>? MXmzNFDjiIoQvF2= MV\EUXNQ NI\GbGpl\WO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDze49tdGWwIH71Z4xmccLi MknZNlQ5PzR5M{S=
OHC NVKzVGlUTnWwY4Tpc44hSXO|YYm= NUm4T2h4OzBy4pEJ{txO M4PRTGROW09? MlTxdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl Mkm3NlQ5PzR5M{S=
OHC M4HOT2Z2dmO2aX;uJGF{e2G7 M4Xw[VMxOOLCid88US=> MUTEUXNQ NVj0dpZU\GmvaX7pd4hmeyCwb3nz[U1qdmS3Y3XkJGFOWEtiYXP0bZZifGmxbh?= MVWyOFg4PDd|NB?=
OHC NF;rdmJHfW6ldHnvckBCe3OjeR?= NF7O[HU{ODEkgJpOwG0> NFKyPFhFVVOR NYDJZ3U1cW6lcnXhd4V{KHSqZTDueY1j\XJib3[gZZBweHSxdHnjJG9JS3Nid3n0bI92fCCjbITldolv\yC2aHWgcIV3\Wy|IH;mJGNEQCCjZoTldkBvd2m|ZTDlfJBwe3W{ZR?= MWGyOFg4PDd|NB?=
SK-Hep1 NU\XO2JZTnWwY4Tpc44hSXO|YYm= NYGxfYFEPjEkgJpOwG3DqA>? NEDXemQyQOLCiXi= MmrQZoxw[2u|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm NIjRVGMzPDh|Mk[wNi=>
SK-Hep1 NV7vOJdiTnWwY4Tpc44hSXO|YYm= M4C4TVYx6oDLzszNxsA> MWGxPQKBkWh? M{PCO4lvcGmkaYTzJO6zNUyjcHHjbI9v\S2rbnT1Z4VlKGynYXvh[4Uhd2ZiSF3HRk0yyqB? NFTzRWIzPDh|Mk[wNi=>
SK-Hep1 MoTZSpVv[3Srb36gRZN{[Xl? MnLKOlDjiIoQvF5CpC=> MYGxPQKBkWh? NEHGb2ZjdG:la4RCpO6zNWyjcHHjbI9v\S2vZXTpZZRm\CCSQWKgZYNkfW23bHH0bY9vKGGwZDDBTWYhfHKjboPsc4NifGmxbjD0c{B1cGViY4n0c5NwdMLi MkewNlQ5OzJ4MEK=
L-540  NWD1V|NCTnWwY4Tpc44hSXO|YYm= M{nJdlYx6oDLzszt MVSx5qCKcA>? MUPwdoV3\W62czD0bIUh\2WwZYLheIlwdiCxZjDSU3M> MUKyOFU3OTVzOR?=
L-540  MWjGeY5kfGmxbjDBd5NigQ>? M{LPNVYx6oDLzszt MnPYNgKBkWh? MkjrdJJmfmWwdIOgeIhmKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? MUiyOFU3OTVzOR?=
L-540  NIm2c|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3vUO|Yx6oDLzszt NWDlVGRUOeLCiXi= MUHy[YR2[2W|IITo[UBIcX[rbn;zeIF1N1OxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGh? MVOyOFU3OTVzOR?=
AGS M{W0TWNmdGxiVnnhZoltcXS7IFHzd4F6 NYnNPZV{PjEkgJpOwI0> M1L1NlHjiImq M37i[JBz\X[nboTzJJNpcWuxbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M133[VI1PDZ|MUm5
NRK-52E  NXzZZ2xtS2WubDDWbYFjcWyrdImgRZN{[Xl? MXGyNEDPxE1? MUCyOEBp MVfwdo91\WO2czDj[YxteyCocn;tJINmdGxiZHXheIgh[2G3c3XkJIJ6KGm|Y3jlcYliKGmwaoXyfS=> MoLKNlQ{PTF6NEW=
NRK-52E  NE\PPHZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnewNlAh|ryP NX6xPIR2OjRiaB?= M{KxOYlv[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25? MVeyOFM2OTh2NR?=
NRK-52E  NFT0XY5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4nhTFIxKM7:TR?= MlHwNlQhcA>? NYLMfZRucW6qaXLpeJMhcW6lcnXhd4VlKES{cEGgdJJwfGWrbjDlfJBz\XO|aX;uJIFnfGW{IGTOSk3PuSCVdHnteYxifGmxbjDhcoQhSVSSIFTldIxmfGmxbh?= MlLpNlQ{PTF6NEW=
L929 MU\GeY5kfGmxbjDBd5NigQ>? NYP6Vo1WOi93wrFOwIcwdW{EoB?= MnfxNlTDqGh? NFjLRVdz\X[ncoPl[EB1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG5H|rFiYXzvcoUh[XNid3XscEBieyCWTldOteKhM8Liem\BSC=> NFnhVFYzOzl2MUe2PS=>
L929 NXnrW|RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPtNk82yqEQvHevcYzDqA>? M1L2UFI1yqCq MYTy[ZZmenOnczD0bIUh[2WubDDndo94fGhiaX7obYJqfGmxbjDhcoQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGTOSu6yKGGub37lJIF{KHenbHygZZMhXE6IzsJCpEvDqHqYQVS= NFnlRWYzOzl2MUe2PS=>
L929 NVvrd2IyTnWwY4Tpc44hSXO|YYm= NULSSpNZOsLizsznM41tyqB? M4\tcVI1yqCq NHLFZ2lxem:vb4TzJINie3Cjc3WtOkApeDJyKTDhZ5Rqfmm2eTDhcoQheHKxY3HzdIF{\S14IHPs[YF3[Wen NFuycGMzOzl2MUe2PS=>
L929 M4rwNWZ2dmO2aX;uJGF{e2G7 MkXYOeKh|rypL33s MVWyOOKhcA>? M1nmVYJtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=> NYfXXG9IOjN7NEG3Olk>
C6 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmrqNUBudW:uL1y= NEjUb3k{KGh? MUjheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi= NVPmeJY4OjN6NEC0OFE>
U87 MkTXR4VtdCCYaXHibYxqfHliQYPzZZk> MUCxJI1ud2xxTB?= NYL1[2d{OyCq M4O4OoF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=> M1m0cFI{QDRyNESx
C6 MonsR5l1d3SxeHnjbZR6KEG|c3H5 NWPjZnJTOSCvbX;sM2w> MoLEN{Bp NFfU[JljdG:la4Ogd4hqc2:waX6gbY5lfWOnZDDu[YNzd3Orcx?= NEDXcWMzOzh2MES0NS=>
U87 MXnDfZRwfG:6aXPpeJkhSXO|YYm= NEfTfmEyKG2vb3yvUC=> Mnf2N{Bp NUjGdWFD[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:|aYO= M1jx[|I{QDRyNESx
C6 MnL5SpVv[3Srb36gRZN{[Xl? NG\QN4MyKG2vb3yvUC=> M{fHZ|EvPS1|IHi= NYTEVnZye3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCUSWCtNUBk[XW|ZXSgZpkhe2ira3;ubY4> M321e|I{QDRyNESx
U87 NH\DVlRHfW6ldHnvckBCe3OjeR?= MYWxJI1ud2xxTB?= MkPBNU42NTNiaB?= NGPLfm5{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=> NFjoXFkzOzh2MES0NS=>
TE671 Mlz3R4VtdCCYaXHibYxqfHliQYPzZZk> M4q2dFQx6oDLzsznM41tyqB? NYixZ|dWOjRiaB?= M3vEPZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 MluwNlM4PDR{OU[=
RMS13 M17xN2NmdGxiVnnhZoltcXS7IFHzd4F6 NUPaeo1yPDEkgJpOwIcwdW{EoB?= MWmyOEBp Mmm2doV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> NWqyTVM3OjN5NESyPVY>
MEFs NH7Gd4tEgXSxdH;4bYNqfHliQYPzZZk> NETyc5UzNzZxMkCg{txO NVvUZZc2OThiaB?= M2DLNIlvcGmkaYTzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aDDpckBT\WyDIFvPJG1GTnN? NYTR[mF5OjN5Mke1PFE>
MEFs M{\0[WZ2dmO2aX;uJGF{e2G7 M1jvUFIxyqEQvF2= M3S4flEwOi92IHi= MYHzeZBxemW|c3XzJHRPTs7zLXnu[JVk\WRiUlnQT|EheGixc4Doc5J6dGG2aX;u NXu0[3Q4OjN5Mke1PFE>
ΔN-Karpas 299  Ml3NR5l1d3SxeHnjbZR6KEG|c3H5 NWLqfYFSOjEEoN88US=> NFXGRmEyPiCq NF;iOG9qdmirYnn0d{BETDNyLXnu[JVk\WRiY3XscEBl\WG2aB?= Mle0NlM2PDV7M{i=
MM.1S  MYnDfZRwfG:6aXPpeJkhSXO|YYm= NE\T[HY6OCEEtV2= NWewZpAyOSCq NXPzNpFU[myxY3vzJGJCYSBzMT23NFgzKGmwZIXj[YQhemGyaXSgZ4VtdCC|d3XscIlv\w>? MlvQNlM2OjdzNUS=
KMS-12-BM M4PNN2N6fG:2b4jpZ4l1gSCDc4PhfS=> NWjETXF4QTBiwsXN MmXxNUBp M4DHSIJtd2OtczDCRXkhOTFvN{C4NkBqdmS3Y3XkJJJieGmmIHPlcIwhe3enbHzpcoc> M4\sW|I{PTJ5MUW0
HT-22  M33TfmNmdGxiVnnhZoltcXS7IFHzd4F6 NHu2eVIyOMLizszN Mo\tNVLDqGh? NUK3V|cyTE2VTx?= Mln3dJJwfGWldIOgZYdicW6|dDDncJV1[W2jdHWtbY5lfWOnZDDj[YxtKGSnYYTo NXL3NY5qOjN|MEe3OVI>
HT-22  NXT0PYZYTnWwY4Tpc44hSXO|YYm= M4riTFI2yqEQvF2= NVnpXFl[OOLCk{OwxsBucW5? M1[2ZWROW09? MnPxbY5pcWKrdIOgSXJMKEGldHn2ZZRqd25iaX7keYNm\CCkeTDncJV1[W2jdHW= Mn;nNlM{ODd5NUK=
NIH3T3  MXXGeY5kfGmxbjDBd5NigQ>? NEXudmgyOC93MDFOwG0> MYexM|MhcA>? MV3hcYVtcW:{YYTld{BVVkcQsT3kdol3\W5iY3;tdIxmgCCob4LtZZRqd25? MXyyN|I3OTZ5Nx?=
SH-EP NHz6UmtCeG:ydH;zbZMhSXO|YYm= NV;wR3RJOTEkgJpOwG3DqA>? M3K4cVcz6oDLaNMg NYnVTpJwcW6qaXLpeJMhUUGSIHnubIljcXSxcj2gZY5lKEyneHH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m| MYeyNlg6ODN{Mh?=
HL60 MYDBdI9xfG:|aYOgRZN{[Xl? MVm2NEDPxE1? M{TTdlEzKGh? Moiw[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MYKyNlg{PzZ6OR?=
HL60/Adr NEPOWXhCeG:ydH;zbZMhSXO|YYm= M4TDV|YxKM7:TR?= MVKxNkBp MXXlcohidmOnczDzbIlsd26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= NID5NJMzOjh|N{[4PS=>
K562 MWTBdI9xfG:|aYOgRZN{[Xl? MYO2NEDPxE1? MnKxNVIhcA>? NE\PcGJmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MX[yNlg{PzZ6OR?=
K562/Adr  M2ewcWFxd3C2b4Ppd{BCe3OjeR?= MlnSOlAh|ryP NXPk[G43OTJiaB?= NGDuTnBmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> M2nEd|IzQDN5Nki5
HL60 NIPtSIdHfW6ldHnvckBCe3OjeR?= MnLTOlAh|ryP NHywSWEyOiCq Mk\zZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? MVqyNlg{PzZ6OR?=
HL60/Adr NHH1dINHfW6ldHnvckBCe3OjeR?= MXe2NEDPxE1? M2fhPFEzKGh? NIjqPY1ifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 NITwd3AzOjh|N{[4PS=>
K562 Mnj2SpVv[3Srb36gRZN{[Xl? MV:2NEDPxE1? MVqxNkBp NETvU4VifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 MVmyNlg{PzZ6OR?=
K562/Adr  MnL1SpVv[3Srb36gRZN{[Xl? MkfVOlAh|ryP MYmxNkBp NImweoxifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 MWWyNlg{PzZ6OR?=
HL60 NFX3UmNHfW6ldHnvckBCe3OjeR?= NU\pR2dOPjBizszN M{DQd|EzKGh? M{W1Nolv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= M1rTOVIzQDN5Nki5
HL60/Adr MlHTSpVv[3Srb36gRZN{[Xl? NXLjflZKPjBizszN MV2xNkBp MYHpcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? NWD2Z2hXOjJ6M{e2PFk>
K562 NUHoeoJbTnWwY4Tpc44hSXO|YYm= NVXIZXBpPjBizszN Mlq1NVIhcA>? M3m5fIlv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= MYmyNlg{PzZ6OR?=
K562/Adr  MUDGeY5kfGmxbjDBd5NigQ>? NIjEdoQ3OCEQvF2= NX;lWoJUOTJiaB?= NX:xZ25lcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 NYjDdlFqOjJ6M{e2PFk>
L929sA MljtRZBweHSxc3nzJGF{e2G7 M2r5TFExKM7:TR?= MVmxJIg> NWXjRYlScW6qaXLpeJMhfGinIHHwc5B1d3SrYzDy[ZNxd26|ZTD0c{BVVkZ? MXWyNlM3Ojd4Nx?=
L929sA MU\BdI9xfG:|aYOgRZN{[Xl? MUWxNEDPxE1? MoHhNUBp NFOxOpZz\XOldXXzJINmdGy|IHX4dJJme3OrbnegVmlRUzIQlFnEJIZzd21iVF7GMYlv\HWlZXSgZZBweHSxc3nz Ml\1NlI{PjJ5Nke=
L929sA M2\LbGFxd3C2b4Ppd{BCe3OjeR?= NGn3SnEyOCEQvF2= NGjxTncyKGh? NGjLNo9i[nKxZ3H0[ZMhfGinIHnueIVz[WO2aX;uJI9nKGOjc4Dhd4UuQCC5aYToJGZCTER? NFW4d2QzOjN4Mke2Oy=>
TPC-1 NUDQZ3hoS2WubDDWbYFjcWyrdImgRZN{[Xl? M1K2dFExOCEQvF2= M{DMZlI1KGh? NYXne3VmTE2VTx?= MULpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MkDZNlIyOzZ6MUi=
8505c MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn\yNVAxKM7:TR?= MWSyOEBp M3vRU2ROW09? MW\pcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MWKyNlE{PjhzOB?=
SW13 MnnjR4VtdCCYaXHibYxqfHliQYPzZZk> M1ftcFExOCEQvF2= NYXTb5cyOjRiaB?= NVXyN3l4TE2VTx?= MVLpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= NV7ndIlFOjJzM{[4NVg>
Jurkat  MYfDfZRwfG:6aXPpeJkhSXO|YYm= NGLQOm82OC9iMUCwM|IxOMLizszt NHjubGsyNzNiaB?= NUftXFN4emWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBkgXSxdH;4bYNqfHl? NYDoXXN1OjF3M{WwNlA>
Jurkat  NIfGW2pHfW6ldHnvckBCe3OjeR?= MV[yNFDDqM7:bR?= NFzQfWo{OCCvaX6= M{nWbpJm\HWlZYRCpG5i\WeuZYLpZUBnd3euZYLpMYlv\HWlZXSgdoVi[3SrdnWgc5h6\2WwIIPw[YNq\XNiKGLPV{kh\2WwZYLheIlwdg>? NV3hNlE2OjF3M{WwNlA>
HT-22 M{\VOWN6fG:2b4jpZ4l1gSCDc4PhfS=> MmLJNVAh|ryP MVexNkBp MnjNdJJwfGWldIOgZYdicW6|dDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhPcLibX3vcE9NKGeudYThcYF1\cLi NHrXVVQyPzd4MEi2PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

RIP1 激酶检测:

RIP1 的磷酸化需要其激酶活性。FLAG标记的野生型(WT)或RIP1(K45M) 突变体失活激酶的表达结构转染到293T细胞中,在有[γ-32P]ATP存在时,RIP1激酶实验在30°C下进行30分钟。样品进行SDS-PAGE,通过放射自显影可观察到RIP1带。对放射性带的相对强度进行量化,并显示比率。在激酶反应的同时,珠样本使用anti-RIP1抗体进行Western Blot分析,确保与激酶反应中等量的蛋白。
细胞实验:

[2]

- 合并
  • Cell lines: Jurkat, BALB/c 3T3, SV40-转化的MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    细胞接种在96孔板中(白色板进行发光检测;黑色板进行荧光检测;空白板进行MTT实验)贴壁细胞按每孔5000-10000个细胞的密度接种,悬浮细胞按每孔20,000-50,000个细胞的密度接种,孔中含100 μl合适的无酚红培养基。温育后,使用如下方法之一测定细胞存活率。ATP 实验中,使用购买的发光试剂盒,并使用Wallac Victor II酶标仪分析发光值。Sytox实验中,细胞与 1 μM Sytox Green试剂在37°C下温育30分钟,然后进行荧光读数。随后,增加5 μl 20% Triton X-100溶液到每孔中,产生最大溶解,细胞37°C下温育1小时,然后进行二次读数。Triton处理前和后,计算值的比率。MTT实验,使用CellTiter 96 AQueous 非放射性细胞增殖检测试剂盒。PI排除实验中, 加入2 μg/ml PI 到培养基中,立即使用FACSCalibur分析样品。PI-膜联蛋白V 实验中,使用ApoAlert Annexin V-EGFP 凋亡试剂盒。进行DioC6染色, 细胞与40 nM DiOC6 在37°C下温育30分钟, 洗涤一次,使用FACSCalibur分析。ROS分析中, 细胞与5 μM Dihydroethidium在37°C下温育30分钟, 洗涤一次,使用FACSCalibur分析。


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+45% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 259.33
化学式

C13H13N3OS

CAS号 4311-88-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Necrostatin-1 | Necrostatin-1供应商 | 采购Necrostatin-1 | Necrostatin-1价格 | Necrostatin-1生产 | 订购Necrostatin-1 | Necrostatin-1代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID